Oxovasin is a therapeutic agent for the local treatment of wounds and wound healing disorders. The effectiveness of Oxovasin solution is based on the influence on the wound repair mechanism. This is demonstrated by an improved wound cleansing. Oxovasin also improves the formation of granulation tissue and leads to a wound closure by means of influencing wound contraction as well as faster epithelization.
Oxovasin is a colourless, aqueous solution. It is usually applied to the wound twice daily. Alternatively, a cotton compress soaked in Oxovasin can be placed on the wound. For a wound the size of 10 x 10cm which can be covered by a folded sterile cotton compress of equal size, 5ml of Oxovasin should be sufficient. For more information, please consult the package insert and the section ‘Application’ of this website.
Pack sizes and recommended retail prices (Germany) for pharmacies:
Oxovasin is sold through pharmacies as follows:
|Package size||Recommended retail price including sales tax|
|Packaged goods for hospitals:|
|10 x 50ml|
|10 x 100ml|
Larger packages are available for hospitals (details and price list available on request). Please note that we exclusively deliver to pharmaceutical wholesalers, hospitals, and pharmacies.
5ml of solution contains:
Reaction product 6.9 x 106 U.*)
Produced from: 10.28mg sodium chlorite, 1.38mg sodium hypochlorite,
0.75mg sulfuric acid 69%, 0.6µg potassium chlorate,
0.37mg sodium carbonate – hydrogen peroxide (2:3),
1.09mg sodium peroxide
*) 1U. = 1 pmol ethylene, released by aminocyclopropanoic acid in the presence of hemin as the activator during quantitative determination
Glycerol, Purified water
Therapeutic group/Mode of Operation
Wound healing agent
Treatment of wounds and wound healing disorders by improvement of wound cleansing, of granulation, of epithelization, and of would closure, including:
Oxovasin solution should not be applied in case of hypersensitivity against Oxoferin/Oxovasin or one of the other ingredients contained in Oxovasin. In pregnant women and infants, Oxovasin should only be used in life-threatening cases, as observations on humans are not available. Experimental studies did not give any hints of teratogenic effects.
Precautions and warnings for use
Due to its mode of action, Oxovasin should be used as a monotherapeutic agent. The application of additional topical drugs to the wound should be avoided under all circumstances, since besides the possibility of a chemical interaction most disinfectants or dye solutions counteract the effect of granulation promoted by Oxovasin.
Oxovasin should not be applied to the wound in combination with other externally used medications or colorants such as brilliant green, gentian violet, fuchsine, and malachite green as this may lead to the loss in the activity of the major ingredient.
In rare cases (≥ 1/10,000, < 1/1,000) the application of Oxovasin solution resulted in hypersensitivity reactions (allergic contact dermatitis) caused by the active ingredient. In uncommon cases (≥ 1/1,000, < 1/100) reddening of the skin, itching or burning sensations and in rare cases mild pain may appear in the wound region at the beginning of the treatment.
As assessory symptoms and signs of wound healing were noted:
Reddening of the wound margin, Itching, burning sensation, mild pain, wound secretion with Ulcus cruris and Decubitus, Spontaneous bleeding, Wound expansion.
These accompanying appearances as noted above may be due to the exudation preceding the restorative phase of wound healing. These appearances are predominantly seen in the treatment of venous ulcers in the lower leg and will normalize themselves in course of treatment.
If hypersensitivity reactions are observed in the area surrounding the wound, the treating physician has to be informed.
Instructions and Declaration of the Shelf Life of the Drug
The expiration date is printed on the outer box and the label on the bottle. Do not use this product after this expiration date! Oxovasin bottles for multiple uses must be securely fastened after use and stored in a dark place; otherwise the effectiveness may be lessened. Contact between the bottle opening and the skin or wound should be avoided. The solution must not be used more than 14 days after opening of the bottle. Oxovasin solution is to be stored in the packaging carton, protected from sunlight. Oxovasin solution should not be stored at a temperature higher than 25 °C.
Drug approval no. and date
19052.00.00 – 2 June 1994
Oxovasin is available as OTC in pharmacies.
Oxovasin 100 ml (top) and 50 ml (bottom), packing and bottle